Olanzapine and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is found among people who take Olanzapine, especially for people who are female, 40-49 old, have been taking the drug for 6 - 12 months.

The phase IV clinical study analyzes which people take Olanzapine and have Multiple sclerosis. It is created by eHealthMe based on reports of 47,890 people who have side effects when taking Olanzapine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 30, 2022

47,890 people reported to have side effects when taking Olanzapine.
Among them, 33 people (0.07%) have Multiple sclerosis.


What is Olanzapine?

Olanzapine has active ingredients of olanzapine. It is often used in bipolar disorder. eHealthMe is studying from 48,451 Olanzapine users for its effectiveness, alternative drugs and more.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,977 drugs and 1,244 conditions by eHealthMe.

Number of Olanzapine and Multiple sclerosis reports submitted per year:

Could Olanzapine cause Multiple sclerosis?

Time on Olanzapine when people have Multiple sclerosis *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 100 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Multiple sclerosis when taking Olanzapine *:

  • female: 83.87 %
  • male: 16.13 %

Age of people who have Multiple sclerosis when taking Olanzapine *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 61.54 %
  • 50-59: 23.08 %
  • 60+: 15.38 %

Common drugs people take besides Olanzapine *:

  1. Movicol: 9 people, 27.27%
  2. Risperidone: 7 people, 21.21%
  3. Clozaril: 7 people, 21.21%
  4. Tecfidera: 5 people, 15.15%
  5. Fluoxetine: 4 people, 12.12%
  6. Zyprexa: 4 people, 12.12%
  7. Cymbalta: 3 people, 9.09%
  8. Seroquel: 3 people, 9.09%
  9. Suboxone: 2 people, 6.06%
  10. Myrbetriq: 2 people, 6.06%

Common side effects people have besides Multiple sclerosis *:

  1. Gait Disturbance: 12 people, 36.36%
  2. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 11 people, 33.33%
  3. Fall: 11 people, 33.33%
  4. Weakness: 10 people, 30.30%
  5. Demyelination (loss of the myelin covering of some nerve fibres resulting in their impaired function): 10 people, 30.30%
  6. Posture Abnormal: 9 people, 27.27%
  7. Muscle Rigidity (muscle stiffness): 9 people, 27.27%
  8. Drowsiness: 9 people, 27.27%
  9. Pain: 6 people, 18.18%
  10. Drug Ineffective: 5 people, 15.15%

Common conditions people have *:

  1. Constipation: 9 people, 27.27%
  2. Urge Incontinence (urinary incontinence): 9 people, 27.27%
  3. Psychotic Disorder: 9 people, 27.27%
  4. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 6.06%
  5. Paranoia (psychotic disorder characterized by delusions of persecution with or without grandeur): 2 people, 6.06%
  6. Urinary Incontinence (inability to control the flow of urine and involuntary urination): 2 people, 6.06%
  7. Pain: 2 people, 6.06%
  8. Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 1 person, 3.03%
  9. Progressive Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord): 1 person, 3.03%
  10. Sleep Disorder: 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Olanzapine and have Multiple sclerosis?

Check whether Multiple sclerosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of Olanzapine:

Multiple sclerosis treatments and more:

COVID vaccines that are related to Multiple sclerosis:

How severe was Multiple sclerosis and when was it recovered:

Expand to all the drugs that have ingredients of olanzapine:

Common drugs associated with Multiple sclerosis:

All the drugs that are associated with Multiple sclerosis:

Common conditions associated with Multiple sclerosis:

All the conditions that are associated with Multiple sclerosis:

How the study uses the data?

The study uses data from the FDA. It is based on olanzapine (the active ingredients of Olanzapine) and Olanzapine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: